Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04538781 · ClinicalTrials.gov registry record
AMBULATE VASCADE MVP Same Day Discharge Retrospective Registry
A clinical trial of Atrial Fibrillation, sponsored by Cardiva Medical.
- Completed
- Registry status
- 497
- Enrollment target
- 4
- Study locations
NCT04538781: Completed study of Atrial Fibrillation, sponsored by Cardiva Medical.
NCT04538781 is a study of Atrial Fibrillation that has completed, run by Cardiva Medical. The registered enrollment target is 497 participants, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (83% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04538781, a study of Atrial Fibrillation, has completed, sponsored by Cardiva Medical.
- COMPLETED
- Registry status
- 497 participants
- Enrollment target
- 4
- Study locations
Study Summary
A multi-center, retrospective, single arm post market registry to evaluate procedural outcomes data using the Cardiva VASCADE MVP Venous Vascular Closure System (VVCS) for the management of the femoral venotomy after catheter-based atrial fibrillation interventions with or without another arrythmia performed via 6-12F procedural sheaths with single or multiple access sites per limb for patients who are discharged the same day.
Primary Outcome
Primary Performance Outcome
Conditions Studied
Interventions
- DEVICE VASCADE MVP VVCS
Study Locations (4)
California
- Coastal Cardiology - San Luis Obispo
District of Columbia
- MedStar Washington - Washington D.C.
Massachusetts
- Lahey Clinic - Burlington
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 497 participants |
| Start Date | 2020-10-09 |
| Est. Completion | 2021-02-08 |
What the finished NCT04538781 record still lists
NCT04538781 is an observational study that tracks outcomes without assigning an intervention. The registered 497 participants enrollment target is mid-sized for trials with a published cap, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which VASCADE MVP VVCS is the first listed.
NCT04538781 reports a single indexed study location in California, District of Columbia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04538781 about?
NCT04538781 is a clinical study titled "AMBULATE VASCADE MVP Same Day Discharge Retrospective Registry". A multi-center, retrospective, single arm post market registry to evaluate procedural outcomes data using the Cardiva VASCADE MVP Venous Vascular Closure System (VVCS) for the management of the femoral venotomy after catheter-based atrial fibrillation interventions with or without another arrythmia ...
What is the current status of trial NCT04538781?
This trial is currently completed. The enrollment target is 497 participants. The study started on 2020-10-09. Estimated completion is 2021-02-08.
What conditions does trial NCT04538781 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT04538781?
The interventions under investigation include: VASCADE MVP VVCS (DEVICE).
Who is sponsoring clinical trial NCT04538781?
This trial is sponsored by Cardiva Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04538781 being conducted?
This trial has 4 study locations across California, District of Columbia, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04538781's enrollment target sits among peer trials
497 60th of 202 higher than 143 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
- NCT05766670 · 497 participants · Phase 3
Intramedullary Calcium Sulfate Antibiotic Depot
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI